



Department of Medicine, Division of Gastroenterology & Hepatology
513 Parnassus Avenue, Box 0538
San Francisco, California 94143-0538
Tel: (415) 476-2776 | Fax: (415) 476-0659

To Whom It May Concern:

I am writing in my capacity as the UCSF Director of Hepatology and Medical Director of Liver Transplantation to express my wholehearted support for the proposed initiative to integrate Dr. Ge's liver-specific Large Language Model ("LiVersa") into his cirrhosis management clinical decision support system ("CirrhosisRx"). This effort promises to significantly improve the quality of care for patients with cirrhosis and to facilitate evidence-based decision-making across our hepatology and transplant programs.

As you know, the management of advanced liver disease is nuanced and rapidly evolving. Clinicians often have to sift through complex guidelines and patient data under pressing clinical scenarios. A specialized integrated LLM, capable of referencing authoritative guidelines and synthesizing real-time patient information, has the potential to streamline this process. In particular, embedding such a resource within the routine clinical workflow could enhance guideline-specific clinical care, improve efficiency and efficacy of our clinicians, and realize personalized medicine.

From an operational standpoint, the UCSF Hepatology and Liver Transplant programs stand to benefit greatly from potential improvements in quality of care and outcomes, specifically related to morbidity and readmissions related to cirrhosis complications. Moreover, the initiative to merge two core electronic technologies within our UCSF Liver Center's research program into an integrated solution for cirrhosis care helps to maintain UCSF Liver Transplant Program's reputation as a national leader in the management of advanced and end-stage liver disease.

Our hepatology and transplantation teams are poised to collaborate by providing relevant clinical insights, championing end-user engagement, and contributing to performance evaluations that measure impact on patient outcomes.

Thank you for considering this valuable initiative. I look forward to seeing its impact on improving care for our patients with advanced liver disease. Please feel free to contact me if additional information or support is needed.

Sincerely,

DocuSigned by:

3/31/2025

Francis Yao

Francis Yao, MD., FAASLD
Professor of Clinical Medicine and Surgery
Director, Hepatology
Medical Director, Liver transplantation
University of California, San Francisco